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Teaser: This review summarizes the critical quality attributes of biosimilarity, also introducing the glycosimilarity index as 
an additional parameter to prove similarity between innovator and biosimilar products. 
 
Highlights 
 The critical quality attributes of biosimilarity are reviewed 
 Regulatory and statistical considerations are summarized. 
 Importance of glycosylation analysis during biosimilar production is detailed. 
 Analytical methods to track N-glycosylation patterns are reviewed. 
 Glycosimilarity index is introduced. 
 
The recent expiration of several protein therapeutics opened the door for biosimilar development. Biosimilars are 
biologic medical products that are similar but not identical copies of already-authorized protein therapeutics. Critical 
quality attributes (CQA), such as post-translational modifications of recombinant biotherapeutics, are important for the 
clinical efficacy and safety of both the innovative biologics and their biosimilar counterparts. Here, we summarize 
biosimilarity CQAs, considering the regulatory guidelines and the statistical aspects (e.g., biosimilarity index) and then 
discuss glycosylation as one of the important attributes of biosimilarity. Finally, we introduced the ‘Glycosimilarity 
Index’, which is based on the averaged biosimilarity criterion. 
 
Keywords: average bioequivalence; biosimilarity index; glycosylation pattern; glycosimilarity index. 
 
Introduction: biosimilar market overview 
The term ‘biologics’ covers a range of recombinant protein pharmaceuticals, such as hormones, growth factors, 
blood products, monoclonal antibody-based therapeutics, fusion proteins, antibody–drug conjugates, and 
recombinant vaccines. They have become an essential part of the modern pharmaceutical palette and represent a 
rapidly growing section of the pharmaceutical industry [1]. As of May 2017, 74 antibody-based molecules had been 
approved by regulatory authorities all over the word. Furthermore, there are 70 antibody-based molecules 
currently in Phase III and 575 in Phase I/II clinical trials [2]. Spending on biologics development between 2013 and 
2014 increased by 32.4%, whereas spending on small-molecule drugs only increased by 6.8% over the same 
timeframe. Based on this trend, an annual increase of 16% is expected from 2015 to 2018. The Global & USA 
Biosimilar Market Analysis from 2015 estimated that the USA will be the largest market for biosimilars, 
contributing 4–10% of the global biologics market by 2020, depending on the number of biosimilars approved by the 
US Food and Drug Administration (FDA) [3]. 
Eli Lilly’s insulin (developed by Genentech, Inc.) was one of the first recombinant protein drugs on the market, 
introduced during the 1980s [4], followed by dozens of biotherapeutics for the treatment of different diseases [5,6]. 
In recent years, the patents and regulatory data protection periods for many of those original recombinant protein-
based biotechnological medicines started to expire, opening the door for other companies to develop their own 
versions, dubbed ‘biosimilars’ [4]. As the generally accepted nomenclature suggests, biosimilars are similar but not 
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exactly the same as the original innovator products. Biosimilars, in most instances, are produced using different 
cell lines and manufacturing and purification processes; therefore, the final product is not identical to the 
originator [7]. During biosimilar development, the following important issues should be addressed: (i) verification of 
similarity; (ii) interchangeability of biosimilars and original innovator product; (iii) unique naming of the biosimilar 
for differentiation; (iv) regulatory framework; (v) regulatory guidelines to assist manufacturers in product 
development; (vi) intellectual property (IP) rights; and, last but not least, (vii) safety [1]. 
Here, we summarize the attributes, including statistical aspects (e.g., biosimilarity index) of biosimilarity in 
light of regulatory guidelines. We then discuss glycosylation, one of the important attributes of biosimilarity, 
,focusing particularly on the control of glycosylation processing and the analysis of the resulting glycosylation 
pattern during all stages of biosimilar production. 
Attributes of biosimilarity 
Main characteristics of biosimilarity 
The exact definition proposed for biosimilars in accordance with European Medicines Agency (EMA), FDA, and 
WHO guidelines is as follows: ‘Biosimilars are copy version of an already authorized biological medicinal product 
with demonstrated similarity in physicochemical characteristics, efficacy and safety, based on a comprehensive 
comparability exercise’ [8]. Thus, a biosimilar should be highly similar to the reference medicinal product based on 
its physicochemical and biological properties. Comparable clinical safety and efficacy of the biosimilar and the 
reference product should also be confirmed [9]. Immunogenicity is one of the most-cited safety concerns of 
biosimilars; therefore, the corresponding clinical data are crucial before approval [10]. Any observed differences 
have to be properly justified because they could have potential impact on the clinical performance [9]. Whereas 
biosimilars are copy versions of the innovator products, biobetters are biologics with structural changes, better 
functional targeting, or an improved formulation that can result in improved clinical safety and efficacy compared 
with the innovator product [11]. 
During biosimilar development, a step-wise approach is recommended, starting with comprehensive 
physicochemical and biological characterization with proper and preferably orthogonal analytical methods [12]. The 
clinical data needed to support biosimilarity are influenced by the evidence obtained in the preclinical in vivo 
studies, namely during physicochemical and biological characterization [13]. Differences in molecular structure 
(e.g., post-translational modifications, higher order structures, etc.) are often assessed through rigorous analytical 
testing. Molecular structure parameters represent the CQAs relevant to the clinical outcomes between a proposed 
biosimilar and the reference product, referred to as an ‘analytical similarity assessment’ [14]. A step-wise approach 
is adopted to confirm biosimilarity and interchangeability, including: (i) structural and functional characterization; 
(ii) animal studies, such as toxicity, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity; and (iii) 
clinical studies to assess and validate safety, efficacy, and immunogenicity issues in humans [15]. 
Regulatory requirements 
According to FDA Guidelines, proper analytical methodologies with good sensitivity and specificity should be 
applied during the structural characterization of therapeutic proteins. The biosimilar product and the reference 
product should be compared in terms of the following criteria: (i) primary structures, such as amino acid sequence; 
(ii) secondary, tertiary, and quaternary structures; (iii) post-translational modifications, such as glycosylation, 
phosphorylation, and so on; (iv) degradation hotspots, such as protein deamidation and oxidation; and (v) chemical 
modifications, such as PEGylation. Biosimilar developers should conduct comprehensive structural head-to-head 
characterization on multiple lots of their biosimilar candidates and the reference products to understand the lot-to-
lot variability in context with manufacturing process parameters. Lots selected for the analyses should be 
representative to demonstrate biosimilarity between the candidate and reference products. Selection of the 
representative lots and the number of lots to be analyzed should also be properly justified [13]. The regulatory 
agencies require accurate characterization of biosimilars based on the above-listed criteria. Physicochemical 
characterization of the innovator product and its biosimilars have been reported in several case studies [16–18]. 
Improvements in product quality are desirable and can be achieved with changes in the manufacturing process; 
therefore, the postchange product can show improvements in clinical efficacy and/or safety compared with the 
prechange product [19]. In the International Conference on Harmonisation (ICH) Q5E Guidelines, comparability is 
defined so that the CQAs of the pre- and postchange products are not identical but highly similar and have no 
harmful effect upon the safety or efficacy of the biosimilar product [19,20]. 
The development process of a biosimilar product starts with an extensive literature search to understand the 
mechanism of action (MoA) of the reference medicinal product for all of the existing indications and to gain 
knowledge about any reported structure- or function-related adverse events or immunogenicity issues. Using the 
collected information, CQAs of the drug can be determined using various risk assessment approaches and their 
criticality can be assessed. Once the CQAs are determined, a comprehensive analytical biosimilarity approach can 
be designed (Figure 1). In the next step, CQAs such as aggregation level, charge variant profile, post-translational 
modifications, and biological activity, are analyzed in several lots of the reference product to assess the quality 
target product profile (QTPP). This step is followed by the selection, design, and development of the expression 
system (expression construct and host cell line) and other steps of the manufacturing process to provide a firm 
foundation to generate the biosimilar product. The CQAs are continuously monitored during manufacturing process 
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development to provide feedback for process parameter changes [5]. Reverse engineering, extensive iterations in 
process development, and analytical characterization are all included in biosimilar development to produce a 
product that is highly similar to the reference material. Given the usually limited information on the originator’s 
manufacturing processes, this process can involve the use of a new cell line, newly developed cell culture conditions, 
purification steps, and, in some instances, a more-contemporary formulation to that used by the originator at the 
time of market entry [21]. 
The predefined biosimilarity criteria should address issues such as the degree of similarity and sensitivity to 
small deviations. Appropriate statistical methods, such as equivalency test, quality range approach, and the 
introduction of the so-called ‘biosimilarity index’, as well as clinical study designs, are all required by the FDA to 
assess biosimilarity with a high level of confidence [15]. 
Statistical considerations and the biosimilarity index 
The FDA suggests using a three-tier approach for analytical similarity assessment. It provides statistical 
methodology guidance to deliver the totality-of-the-evidence for demonstrating biosimilarity. The identified CQAs 
with relevant clinical outcomes are classified into the three tiers based on their risk (i.e., high, moderate, and low 
risk in terms of clinical safety and efficacy). Different statistical approaches for the different tiers are 
recommended, namely equivalency test for CQAs from Tier 1 (high risk), quality range approach for CQAs from 
Tier 2 (moderate risk), and descriptive raw data and graphical presentation for CQAs from Tier 3 (low risk). Chow 
et al. thoroughly described the different statistical approaches in relation to the above [22]. 
The biosimilarity index, or average bioequivalence (ABE) index is a disaggregated, probability-based (PB), 
scaled, and weighted criterion for the assessment of biosimilarity that can be expressed by Equation 1 [23], where T 
(test product, biosimilar) and R (reference product, innovative artifact) are the parameters of interest (e.g., PK 
data). Thus, the biosimilarity index (𝑝𝑃𝐵) between the test and the reference product can be defined as: 
𝑝𝑃𝐵 = (1 − 𝛿 <
𝑇
𝑅
< 1 + 𝛿) [1], 
where 0 < δ < 1 is the biosimilarity limit for the PB method. 
To apply the local biosimilarity index (calculated based on a specific product parameter) between the test and 
the reference product, the following steps have to be followed, as described in [24–26]: (i) assess the average 
biosimilarity between the test product and the reference product based on a set of biosimilarity criteria. The 
criteria could be based on mean, ratio, or variability of the test product parameter. The ratio of means of a given 
study endpoint should fall within the biosimilarity limit of 80–125% for in vivo and 90–111% for in vitro studies 
[27,28]; (ii) calculate the local PB biosimilarity index using Equation 1; and (iii) declare the test product highly 
similar if the 95% confidence lower bound of the biosimilarity index (pPB) is larger than a prespecified number of p0, 
where p0 can be obtained based on an estimate of reproducibility probability for a study comparing a reference 
product to itself. 
The proposed biosimilarity index has the following advantages: (i) it is robust with respect to selected 
biosimilarity criteria for the assessment of bioequivalence; (ii) the index takes variability into consideration and 
sensitive to the variation of the test product; and (iii) it allows the assessment of the degree of similarity, and, thus, 
provides an answer to the question ‘how similar is similar’ [29,30]. 
The biosimilarity (or ABE) index can be also described by a moment-based method with the relative distance (rd) 
based on Equation 2 [31]: 
𝑟𝑑 =
𝑑(𝑇,𝑅)
𝑑(𝑅,𝑅)
 [2], 
where d(T,R) is the difference between the test (T) and reference (R) products, and d(R,R) is the difference between 
several batches of the reference product itself. Typically, a one-sided 95% confidence interval is applied for rd-based 
determination of biosimilarity and/or bioequivalence. If the one-sided 95% upper confidence limit is less than the 
biosimilarity limit, then the test product is considered to be biologically similar to the reference product. In this 
case, based on the traditional average bioequivalence criterion, the biosimilarity index can be defined as (Equation 
3): 
rd = MT/MR  [3], 
and in the case of scaled average bioequivalence criterion (Equation 4): 
rd = (MT–MR)/σR [4], 
where MT is the mean of the test product parameters (e.g., PK data, PD data, and analytical data, such as 
integrated peak area), MR and σR are the mean and standard deviation of the reference product parameters, 
respectively [24]. 
Glycosylation of biosimilars 
Regulation of glycosylation during biosimilar production 
Most recombinant protein biologics and their biosimilars (e.g., monoclonal antibodies, fusion proteins, antibody-
drug conjugates, etc.) are typically glycosylated. Therefore, glycosylation is a CQA and probably one of the most 
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challenging aspects to demonstrate biosimilarity for therapeutic glycoproteins, given the noncoded properties of the 
glycosylation machinery. Glycosylation of biosimilars could have a significant impact on the biological activity, 
stability against proteolysis, PK profile, serum half-life, effector functions, and immunogenicity of the drug 
products [21,32]. Glycosylation particularly influences the two major effector functions of therapeutic monoclonal 
antibodies, namely antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity 
(CDC). For example, terminal galactose (Gal), N-acetylglucosamine (GlcNAc), and mannose (Man) residues affect 
CDC activity, while terminal sialic acid, mannose, core fucose (Fuc), and bisecting GlcNAc affect the ADCC 
function [33–35]. Therapeutic monoclonal antibodies, such as anti-CD20 rituximab (Rituxan®), anti-Her2 
trastuzumab (Herceptin®), antitumor necrosis factor-α (anti-TNF-α) infliximab (Remicade®), and anti-RhD 
(HyperRHO®) are capable of ADCC effector function. The possible antitumor mechanism of rituximab and 
alemtuzumab (Campath-1H) is CDC [33]. The addition of sialic acid to the terminus of the conserved Fc region 
glycan structures transfers IgG antibodies into anti-inflammatory mediators, rendering them capable of 
suppressing autoantibody-driven inflammation [36]. In addition, the relative levels of high-mannose glycans can 
affect some PK properties of therapeutic antibodies. In particular, therapeutic monoclonal antibodies containing 
high mannose (HM) glycans at the Fc region are cleared more rapidly in humans than are other glycoforms [37]. 
Glycan residues, such as α1,3-galactose, β1,2-xylose, α1,3-fucose, and N-glycolylneuraminic acid (Neu5Gc), have a 
highly negative impact on the safety and/or immunogenicity of monoclonal antibodies [38]. Therefore, these 
potentially immunogenic species should be rigorously monitored [39,40]. In a recent study by Jaquez and 
coworkers, the correlation between the percentage of afucosylated and HM glycans as well as FcγRIIIa binding 
activity and ADCC activity were calculated in the case of infliximab and its biosimilars [41]. 
The proper information about the glycosylation profile of a biosimilar product is well recognized as a CQA that 
needs to be tightly monitored and controlled [42]. For example, if the MoA is based on ADCC or CDC functions, core 
fucosylation or galactosylation are chosen, respectively, as CQAs [43]. Heterogeneity of the therapeutic antibody 
glycoforms increases with the diverse set of host cells used by the industry during the manufacturing process, 
which can be critical regarding the resulting effector functions of the product. The relationship between the 
conserved Fc glycosylation and the effector function associated with the clinical activity of therapeutic antibodies 
makes careful analysis and characterization of glycosylation-related CQAs crucial. The information obtained can 
help during the manufacturing process to fine tune the glycosylation profile of the therapeutic antibodies in the 
pipeline [38]. 
Currently approved therapeutic antibodies are produced by mammalian cell cultures, utilizing Chinese hamster 
ovary (CHO), human embryonic kidney (HEK), mouse myeloma (NS0), or mouse hybridoma (SP2/0) cell lines [44]. 
Regula and coworkers performed comprehensive glycosylation analysis of the Human leukocyte receptor IIIa 
(hFcγRIIIa), derived from HEK and CHO cells [45]. They concluded that the expression cell lines chosen highly 
affected the glycopatterns of hFcγRIIIa, whereas the protein sequence and glycosylation sites remained unchanged 
for both cell types. Their results are summarized in Table 1. 
Although non-mammalian cell expression systems have several advantages (e.g., higher production yield, simple 
and inexpensive culturing, etc.) over mammalian cell lines, their utilization in biologics production is hindered 
because of their limited glycosylation machinery and the potential introduction of immunogenic residues. 
Glycoengineering is a promising new tool to ‘humanize’ non-mammalian cell expression systems by methods such 
as gene knockout, RNA interference, enzyme overexpression [46], and genome editing with RNA-guided CRISPR-
Cas9 nuclease systems [47]. As an example, GlycoFi glycoengineering technology is based on a humanized yeast 
cell line of Pichia pastoris that allows the production of human glycoproteins with not only HM, but also complex N-
glycosylation modifications [48]. Furthermore, the glycosylation pattern of a therapeutic glycoprotein produced by 
GlycoFi is comparable to mammalian cell expression systems, such as CHO and NS0 cell lines. Thus, the P. 
pastoris expression system represents a promising approach for the production of large-scale batches of therapeutic 
humanized glycoproteins at lower cost. GlycoDelete is another promising glycoengineering approach, which 
produces proteins with small, sialylated N-glycans and reduces the complexity of the modified mammalian cell 
expression system compared with native mammalian cell lines [49,50]. Therapeutic proteins expressed in 
GlycoDelete-modified cells have reduced N-glycosylation heterogeneity and clearance compared with those 
expressed in wild-type cells and, thus, can lead to increased reproducibility in their production. Predictive 
glycoengineering can also help in the development of biosimilars. For example, the computational method using the 
Markov chain model of glycosylation can predict the quantitative amounts (e.g., nutrients, inhibitors, and enzymes) 
by which glycosylation reaction rates must be perturbed to obtain a specific glycosylation profile [51]. Brühlmann et 
al. developed a parallel design-of-experiment (DoE) approach. Using this method, 17 glycosylation modulator media 
supplements were identified and arranged in five groups based on their effects on glycosylation. After the fed-batch 
culture in 96-deepwell plates with different medium composition, the best-performing glycosylation modulators 
were selected using multivariate analysis, principal component analysis, and decision trees [52]. 
The manufacturing processes of biologics involve many steps, starting with cloning of the desired gene into a 
complementary DNA vector, continued by transferring it into a suitable host cell (e.g., Escherichia coli, yeast, CHO, 
or NS0), production in a bioreactor, and purification and formulation of the biological drug product [53], (Figure 2). 
The chosen cell line, cell growth stage, and process parameters, such as nutrient availability, dissolved oxygen, 
supplements, temperature, pH, operation schedule, and culture modes, can all have significant effects on the 
glycosylation pattern of the biological drug products [54]. Nagy and coworkers extensively reviewed which process 
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parameters affect glycosylation of the therapeutic antibody (produced by mammalian cell lines) and to what extent 
[55]. The presence of sialidases and other glycosidases, released from dead cells, can cause degradation of 
previously assembled glycosylation structures [56]. Moreover, glycan composition can be selectively modified during 
the downstream part of the process in the different purification steps. Therefore, lot-to-lot variability in the 
glycosylation profile is also one of the best indicators of process robustness. 
Analytical methods to track N-glycosylation patterns 
N-glycosylation analysis to characterize therapeutic glycoproteins in the field of process analytical technology is 
vital [57]. There are several excellent reviews focusing on the glycosylation analysis of therapeutic glycoproteins in 
detail [58–63]. N-glycosylation analysis of therapeutic proteins can be performed at three different levels (intact 
protein, glycopeptide, and released glycans), as depicted in Figure 3 [64]. Intact glycoproteins can be analyzed by 
mass spectrometry (MS) via direct infusion or coupling with separation techniques, such as liquid chromatography 
(LC)-MS or capillary electrophoresis (CE)-MS [65,66]. Such top-level analysis also offers information about glycan 
pairing on the two heavy chains of an IgG molecule. The middle-up approach (IdeS digestion and reduction of the 
intact glycoproteins to yield Fc/2, Fd’, and LC fragments) allows more-accurate identification of the glycosylation 
profiles, because the analysis is conducted on subunits of approximately 25-kDa protein fragments. Guillarme and 
coworkers applied HILIC-MS with a wide-pore stationary phase to qualitatively profile the glycosylation patterns 
at the protein level and compared the originator monoclonal antibodies to the their biosimilar counterparts [67,68]. 
In the middle level, after proteolytic digestion of the glycoproteins, LC–MS/MS of CE-MS/MS analysis is usually 
performed. Middle-level analysis can provide information about glycosylation macro- (site occupancy) and 
microheterogeneity (variation of glycan structures at a given site). In bottom-level analyses, the glycans are 
enzymatically or chemically cleaved off from the protein backbone. The released glycans are usually labeled with a 
fluorescent dye and separated by LC or CE, with the option of MS detection. Bottom-level analysis provides 
information about the glycosylation profile and, with the help of exoglycosidase-based sequencing, fine details can 
be obtained about the linkage and positional isomers [69]. Fully automated carbohydrate sequencing by capillary 
electrophoresis was also recently reported [70]. 
Tharmalingam et al. [71] developed a real-time N-glycosylation monitoring (RT-GM) framework to characterize 
the entire time-course of a fed-batch culture. The sample preparation platform utilized microsequential injection 
(mSI), which was coupled with an ultraperformance liquid chromatography (UPLC) system based real-time glycan 
profiling for therapeutic antibody manufacturing. The authors studied manganese (Mn)-induced glycosylation 
changes in a fed-batch culture with this automated analytical system. Mn-supplemented cultures exhibited higher 
galactosylation, and consistent fucosylation and mannosylation levels compared with their control cell culture 
counterparts. The developed real-time N-glycosylation monitoring framework can accelerate process development 
because the information from monitoring the manufacturing steps can be rapidly translated into process control 
and quick feedback decisions. Although comprehensive knowledge of the glycosylation of the final product is an 
important CQA, the time-related N-glycosylation changes are also important, such as loss of sialic acids during the 
storage of the therapeutic protein. 
Mazzeo and coworkers performed LC-based glycosylation profiling of trastuzumab and its biosimilar counterpart 
using fluorescent detection. Their results confirmed that the ratio of individual glycans (quantified by integrated 
peak area) differed between the biosimilar and the reference product [72]. In another case study, Sanchez-De Meloa 
et al. analyzed the glycan profile of trastuzumab and its biosimilar candidates by normal-phase HPLC and MALDI-
TOF-MS [73]. They observed that the relative abundance (peak area %) of the individual glycans on the monoclonal 
antibody candidates were not similar to the reference product. Liu and coworkers used the same normal-phase 
HPLC and MALDI-TOF-MS approaches for the glycosylation analysis of cetuximab and its biosimilar. The glycan 
profile of the biosimilar was in good agreement with the innovator product, although previously not-reported 
aberrant N-linked glycans with NeuAcLac motifs were identified in the biosimilar [74]. Montacir et al. performed 
glycosylation analysis of rituximab and its biosimilar at three different levels [protein (intact mass and subunits Fc 
and HC), glycopeptide, and glycan] with different MS-based analytical methods (e.g., MALDI-TOF-MS). Although 
the glycosylation sites of both were identical, the carbohydrate profiles of the originator and the biosimilar were 
qualitatively similar, but quantitatively heterogeneous [75]. 
Introducing the Glycosimilarity Index 
It is still challenging to determine and describe the level of similarity between two N-glycosylation profiles; 
however, assessing alikeness at the glycosylation level is one of the most crucial parts of an analytical biosimilarity 
study when the reference product is glycosylated. Here, we introduce a glycoanalytical profile-based similarity-
scoring approach, referred to as ‘Glycosimilarity Index’, that can be used to calculate the level of similarity between 
the N-glycosylation profiles of any given reference and test items. 
To assess the N-glycosylation similarity between a biosimilar therapeutic protein and its reference product, first 
all N-glycosylation related attributes (e.g., total fucosylation, galactosylation, sialylation, mannosylation, etc.) and 
their criticality have to be determined. The FDA suggests a three-tier-based approach to rank the different CQAs is 
applicable here too. In this case, as a first approximation, we consider tier ranking to represent a criticality risk 
rating of the N-glycosylation quality attributes with regard to their potential impact on activity, PK/PD, safety, and 
immunogenicity. Glycosylation CQAs most relevant to clinical outcomes will be classified to Tier 1, whereas CQAs 
that are less (mild-to-moderate) or least relevant to clinical outcomes or immunogenicity will be classified to Tier 2 
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and Tier 3, respectively, as described above for the overall biosimilarity [22]. To assess glycoanalytical similarity for 
the respective CQAs between the reference and biosimilar product, the FDA-proposed equivalence tests for CQAs in 
Tier 1, a quality-range approach for CQAs in Tier 2, and raw data comparison or graphical presentation for CQAs 
in Tier 3 are also applicable. To determine the criticality and to assess the appropriate tier ranking of the different 
N-glycosylation-related CQAs, the following questions have to be addressed: (i) does the N-glycosylation have any 
direct or indirect effect on the efficacy of the product? If yes how? (e.g., via effector functions, directly/indirectly 
affecting target binding, influencing protein structure that alters function, etc.); (ii) where are the CQA N-glycans 
located? (Fc, Fab, surface exposed, etc.); (iii) are there any immunogenic sugar residues present? (NGNA, α-Gal, 
etc.); and (iv) what analytical assay is used for N-glycan profiling? (It is important to assess the acceptance range 
that also depends on the performance of the analytical assay). 
First tier ranking along with the assessment criteria is determined for each N-glycosylation-related attribute, 
such as total fucosylation, total mannosylation, total galactosylation, and so on. This allows the calculation of a 
product-specific glycosimilarity index. First, the reference product(s) is(are) analyzed in triplicates. The profiles are 
aligned and normalized using the highest N-glycan peak before the min, max, mean, and standard deviation are 
determined for those points in the separation trace (CE or LC). The migration and/or retention time of each point of 
the profile is converted to glucose units (GU) using a glucose homo-oligomer ladder injected prior and after the 
samples. A virtual ladder, by using the recently introduced triple internal standard approach, is also appropriate 
for GU value calculation [76]. The electropherogram and/or chromatogram is than fractionally divided into different 
GU value sections, based on the major oligosaccharide classes in the profile (neutral, sialylated, HM, and hybrid). 
Tolerance limits are determined for each GU value interval, based on the tier ranking of the N-glycosylation-
related attributes in hand. For each attribute, tolerance limits are defined during tier ranking based on the 
criticality of the attribute, the variation of the reference, and the performance of the glycoanalytical assay. If 
fucosylation and/or afucosylation is assessed as a Tier 2 attribute with a similarity range of mean ±1.5·SD, then 
each GU value interval that represents fucosylated and/or afucosylated structures will be compared using a mean 
±1.5·SD tolerance window. Points between the upper and lower limits are considered as 100% similar, regardless of 
their distances from the mean. The contribution to similarity score of points outside of the limits is calculated using 
a sum of squared distances to average data [77]. The different attribute similarity scores are calculated using 
Equation 5: 
𝐴𝑖 = 𝑌𝑖 + 𝑋𝑖 × ∑
((𝑥𝑢𝑗−𝑥𝑙𝑗)−𝑥𝑗̅̅ ̅))
2
(𝑥𝑠𝑗−𝑥𝑗̅̅ ̅)
2
𝑛
𝑗=1  [5], 
where Ai is the % profile similarity of the ith attribute (i=1,...,n), Yi is the % of points inside the tolerance limits in 
the ith attribute-related GU section, Xi is the % of points outside of the tolerance limits in the ith attribute-related 
GU sections, xuj is the upper limit of the jth point, xlj is the lower limit of the jth point, xj is the mean of jth reference 
material points and xsj is the jth sample point that falls outside the tolerance limits. The final Glycosimilarity Index 
is calculated form the combination of the different attribute similarity scores using Equation 6: 
GI =
∑ (𝐴𝑖+𝐵𝑖)/2
𝑛
𝑖=1
𝑛
 [6], 
where GI is the Glycosimilarity Index, n is the number of attributes and Bi is the % extent similarity of the ith 
attribute. Bi is considered to be 100% if the summed relative amount of the certain glycoforms related to the ith 
attribute is within the predefined tolerance limits. If the summed relative amount of these peaks falls outside the 
range, Bi is calculated using Equation 7: 
𝐵𝑖 =
((𝑏𝑢𝑖−𝑏𝑙𝑖)−𝑏?̅?))
2
(𝑏𝑠𝑖−𝑏?̅?)
2 × 100 [7]. 
The N-glycosylation of the test product is considered to be highly similar to the reference product if the 
glycosimilarity index falls within the 80–100% range. A graphical representation of the glycosimilarity index is 
depicted in Figure 4. 
Concluding remarks 
Recent expirations of the patent protections for many of the original recombinant protein-based biotherapeutics 
provided the opportunity for large-scale biosimilar development. Regulatory authorities require comprehensive 
analysis of protein structure, post-translational modifications, and biological activity during the development 
process of a biosimilar product. These molecular structure parameters represent the CQAs relevant to clinical 
efficacy and safety. Given that most recombinant protein biologics and, consequently, their biosimilar counterparts 
are glycosylated, information about their carbohydrate moiety is an important CQA to demonstrate biosimilarity at 
the glycosylation level (i.e., glycosimilarity). Glycosylation of biosimilars could have a significant impact on the 
biological activity, effector functions, and immunogenicity of the drug products. The Glycosimilarity Index, 
established based on the traditional average bioequivalence criterion biosimilarity index, could serve as an 
additional parameter to support biosimilarity between the innovator and the biosimilar product. 
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Figure captions 
 
 
Figure 1. Biosimilar product development scheme. The process 
s starts with gathering publicly available information on the reference product (e.g., target and the known biology). The sponsor should analyze the physicochemical 
properties of the originator product, namely protein structure, post-translational modifications, and biological activity. The next step is the development of an appropriate 
expression system and manufacturing process for biosimilar production. If regulatory authorities categorize the proposed biosimilar product as ‘highly similar’, a 
targeted approach for clinical testing might be possible. Reproduced, with permission, from [5]. 
 
Figure 2. Typical manufacturing process of biologics with the analytical characterization requirement of the steps. The manufacturing process of biologics starts with 
cloning the relevant gene into a complementary DNA vector and transferring it into a host cell. The appropriate cell line is then selected and expanded in a fermentation 
medium. In the bioreactor, the selected cell line produces the protein defined by the DNA vector. The complex process ends with the purification of the produced 
protein therapeutics. 
 
Figure 3. Top-, middle-, and bottom-level N-glycosylation analysis. Glycosylation analysis can be performed at these three different levels. In top-level analysis, the 
intact glycoprotein is analyzed by mass spectrometry (MS) or by liquid chromatography coupled to mass spectrometry (LC-MS). By examining the masses of the 
different forms of the intact IgG, and comparing with the mass(es) of the deglycosylated IgG, the different glycoforms can be identified. In the middle level, the intact 
protein is digested to larger glycopeptide fragments and analysed by LC-MS or capillary electrophoresis (CE)-MS. From the middle-level analysis, one can gain 
information about glycosylation macroheterogeneity (also referred to as ‘site specificity’). In the bottom-level analysis of glycosylation, the glycans are either chemically 
or enzymatically cleaved off the glycoproteins. The released glycans are labeled with a fluorescent dye and analyzed by LC or CE. The bottom-level analysis supports 
the in-depth microheterogeneity characterization of glycans. Reproduced, with permission, from [64]. 
 
Figure 4. Title. (a) An example for the tolerance limits (red-dotted lines) for the Man5 peak in the profile. Tolerance limits are calculated from the Reference Medicinal 
Product (RMP) inconsistency screening of the different manufacturing lots. For each point of the GU range, the RMP mean and its standard deviation (SD) is calculated 
to determine the lower and upper tolerance limits. Peak area is considered for the total mannosylation calculation. The similarity score is calculated comparing the test 
items total mannosylation to the RMP mean ± 1.5 SD range and calculated the same way as for profile similarity as explained in (b). The compositional similarity score 
considers the similarity scores of each major N-glycosylation attribute, such as afucosylation, mannosylation, sialylation, and terminal galactosylation. Similarity scoring 
system adapted from [77]. 
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Table 1. Cell type-specific N-glycosylation patterns of shFcγRIIIaa,b 
N-glycosylation site Asn-45 Asn-74 Asn-162 
Expression host cell HEK CHO HEK CHO HEK CHO 
Site occupancy [rel. %] >95 >95 >95 >95 >95 >95 
Complex biantennary and hybrid glycans [rel. %] >99 ~90 n.d. ~5 >95 >95 
Complex triantennary glycans [rel. %] n.d. ~10 n.d. ~5 n.d. ~5 
Complex tetraanteannary glycans [rel. %] n.d. n.d. >99 ~90 n.d. n.d. 
Core fucosylated glycans [rel. %] ~80 ~50 >99 >99 >99 >99 
Antennary fucosylated glycans [rel. %] ~15 n.d. n.d. n.d. ~70  
Sialylated glycans [rel. %] ~30 ~25 ~90 >99 ~5 ~80 
aAfter [45]. 
bn.d., not detected. 
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